我们的主要贡献是，持续释放疗法融合了化学疗法和免疫疗法的优势，并且首次将两者通过干预组合并应用于肿瘤内治疗。它通过在肿瘤内持续释放药物来整合局部和全球治疗，并增加了药物作用的浓度和时间，这不仅发挥了局部化学疗法药物的局部抗癌作用，而且还考虑了全身免疫疗法的作用，从而弥补了其他疗法的缺陷，尤其是为了使癌症的新想法和进度促进癌症的转化，尤其是为了使癌症的转化，尤其是在癌症中进行了转化，尤其是为了改善癌症的范围，并构成了较重要的方法。 价值; UMPIC疗法的优点是将肿瘤用作抗原源和自体疫苗，这也符合个性化医学的发展趋势。 And applied to the clinic, hapten combined with chemotherapy drugs for sustained release treatment of pancreatic cancer primary focus, while inducing distal effect, the essence of which is to induce immune response, T-cell-related CD4, CD8, DC, T and NK cells, and B-cell-related tumor autoantibodies: Antibodies to P53, P16, Cmyc, Zeta, IMP1, Koc, Survivin, p62, HCC1 and other oncogenes, this is the first time to find that T and B are involved in the immune response, and the clinical functions of the distal effect and this therapy was selected for "Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (7th edition) jointly formulated by the Chinese Anti-Cancer Association, the National Clinical Medical Research Center for Radiology and Therapy, and the国家介入医学创新联盟发表在《临床放射学杂志》上，第43卷，第19期，第2024页，第1636-1648页。